MedTrace Logo

Fructose-induced Hepatic De Novo Lipogenesis in Adolescents With Obesity

NCT03567837 · Status: TERMINATED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 12

Last updated 2024-03-15

No results posted yet for this study

Summary

In the U.S., dietary fructose has increased in parallel with the increase in obesity and may promote the development of diabetes and other chronic diseases. The largest source of dietary fructose is sweetened beverages that are consumed by adolescents more than any other age group.

This protocol will compare the rates of hepatic de novo lipogenesis (DNL), a process in the liver that changes sugar into fat, in two groups of obese adolescents - one with prediabetes and the other, metabolically healthy. Blood will be sampled before and hourly for 3 hours after the consumption of a fructose-containing beverage. We hypothesize that the pre-diabetic group will show greater DNL in response to fructose. This would support other evidence that increased fructose-induced hepatic DNL is an early mechanism linking dietary sugar to the adverse metabolic sequelae of obesity, including diabetes, fatty liver, dyslipidemia and coronary disease.

Conditions

  • Adolescent Obesity

Interventions

OTHER

Fructose + Glucose Beverage

The intervention is an oral sugar challenge with blood sampling over three hours.

Sponsors & Collaborators

  • Weill Medical College of Cornell University

    collaborator OTHER

  • University of Missouri-Columbia

    collaborator OTHER

  • The Rogosin Institute

    lead OTHER

Principal Investigators

  • Lisa Hudgins, MD · The Rogosin Institute

Study Design

Allocation
NON_RANDOMIZED
Purpose
SCREENING
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
12 Years
Max Age
21 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2018-08-13
Primary Completion
2019-06-04
Completion
2019-06-04

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03567837 on ClinicalTrials.gov